High-dose recombinant vaccine more effective than egg-based standard-dose vaccine among adults aged 50 to 64<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Dec. 14, 2023 (HealthDay News) — A high-dose recombinant influenza vaccine is more effective than standard-dose vaccine among adults aged 50 to 64 years, according to a study published in the Dec. 14 issue of the New England Journal of Medicine<\/em>.<\/p>\n Amber Hsiao, Ph.D., M.P.H., from the Kaiser Permanente Vaccine Study Center in Oakland, California, and colleagues conducted a cluster-randomized observational study to compare the effectiveness of recombinant vaccines as compared with standard-dose vaccines against influenza-related outcomes in adults under the age of 65 years. During the 2018 to 2019 and 2019 to 2020 influenza seasons, facilities routinely administered either a high-dose recombinant influenza vaccine (Flublok Quadrivalent) or one of two standard-dose influenza vaccines to adults aged 50 to 64 years and 18 to 49 years.<\/p>\n Data were included for 1,630,328 individuals aged 18 to 64 years who received vaccines (632,962 in the recombinant-vaccine group and 997,366 in the standard-dose group). The researchers identified 1,386 and 2,435 cases of polymerase chain reaction (PCR)-confirmed influenza diagnosed in the recombinant-vaccine and standard-dose groups, respectively. Among participants aged 50 to 64 years, 2.00 and 2.34 cases per 1,000 tested positive for influenza in the recombinant-vaccine and standard-dose groups, respectively (relative vaccine effectiveness, 15.3 percent). The relative vaccine effectiveness against influenza A was 15.7 percent in the same age group. Compared with the standard-dose vaccines, the recombinant vaccine was not significantly more protective against influenza-related hospitalization.<\/p>\n “Participants between the ages of 50 and 64 years who received the recombinant vaccine had more protection against confirmed influenza than those who received a standard-dose vaccine,” the authors write.<\/p>\n The study was funded by Sanofi, the manufacturer of the Flublok vaccine.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n